{"id":34755,"date":"2021-06-21T13:01:00","date_gmt":"2021-06-21T06:01:00","guid":{"rendered":"https:\/\/www.xinwengao.com\/cn\/pr\/2021062113010034755"},"modified":"2021-06-21T21:39:00","modified_gmt":"2021-06-21T13:39:00","slug":"%e5%92%8c%e9%bb%84%e5%8c%bb%e8%8d%af%e5%ae%a3%e5%b8%83%e7%b4%a2%e5%87%a1%e6%9b%bf%e5%b0%bc%e8%8e%b7%e5%9b%bd%e5%ae%b6%e8%8d%af%e7%9b%91%e5%b1%80%e6%89%b9%e5%87%86%e4%bb%a5%e6%b2%bb%e7%96%97%e6%99%9a","status":"publish","type":"post","link":"https:\/\/www.xinwengao.com\/cn\/pr\/2021062113010034755","title":{"rendered":"\u548c\u9ec4\u533b\u836f\u5ba3\u5e03\u7d22\u51e1\u66ff\u5c3c\u83b7\u56fd\u5bb6\u836f\u76d1\u5c40\u6279\u51c6\u4ee5\u6cbb\u7597\u665a\u671f\u80f0\u817a\u795e\u7ecf\u5185\u5206\u6ccc\u7624"},"content":{"rendered":"<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/www.xinwengao.com\/cn\/wp-content\/uploads\/HUTCHMED_Logo-3.jpg\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><p>&#8211;&nbsp;\u82cf\u6cf0\u8fbe&reg;\u5728\u4e2d\u56fd\u83b7\u6279\u7684\u7b2c\u4e8c\u9879\u65b0\u836f\u4e0a\u5e02\u7533\u8bf7 &#8211;<\/p>\n<p>&#8211;&nbsp;SANET-p\u5173\u952e\u6027III\u671f\u7814\u7a76\u663e\u793a\uff0c\u7d22\u51e1\u66ff\u5c3c\u964d\u4f4e\u665a\u671f\u80f0\u817a\u795e\u7ecf\u5185\u5206\u6ccc\u7624<br \/>\u60a3\u8005\u7684\u75be\u75c5\u8fdb\u5c55\u6216\u6b7b\u4ea1\u98ce\u9669\u8fbe51% &#8211;<\/p>\n<p><span id=\"spanHghlt125b\">\u9999\u6e2f<\/span>2021\u5e746\u6708<span id=\"spanHghlt807a\">21<\/span>\u65e5 \/\u7f8e\u901a\u793e\/ &#8212; \u548c\u9ec4\u533b\u836f\uff08\u4e2d\u56fd\uff09\u6709\u9650\u516c\u53f8\uff08\u7b80\u79f0\u201c<u><a target=\"_blank\" href=\"https:\/\/www.hutch-med.com\/sc\/home\/\" rel=\"nofollow noopener\">\u548c\u9ec4\u533b\u836f<\/a><\/u>\u201d\u6216\u201cHUTCHMED\u201d\uff09\uff08\u7eb3\u65af\u8fbe\u514b\/\u4f26\u6566\u8bc1\u4ea4\u6240\uff1aHCM\uff09\u4eca\u65e5\u5ba3\u5e03\u7d22\u51e1\u66ff\u5c3c\u6b63\u5f0f\u83b7\u4e2d\u56fd\u56fd\u5bb6\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\uff08\u201c\u56fd\u5bb6\u836f\u76d1\u5c40\u201d\uff09\u6279\u51c6\u7528\u4e8e\u6cbb\u7597\u665a\u671f\u80f0\u817a\u795e\u7ecf\u5185\u5206\u6ccc\u7624\uff08pNETs\uff09\u3002\u8fd9\u662f\u7ee7\u7d22\u51e1\u66ff\u5c3c\u4e8e 2020\u5e7412\u6708\u5728\u4e2d\u56fd\u83b7\u6279\u7528\u4e8e\u6cbb\u7597\u665a\u671f\u975e\u80f0\u817a\u795e\u7ecf\u5185\u5206\u6ccc\u7624\uff08epNETs\uff09\u4e4b\u540e\uff0c\u7d22\u51e1\u66ff\u5c3c\u7b2c\u4e8c\u9879\u83b7\u6279\u7684\u65b0\u836f\u4e0a\u5e02\u7533\u8bf7\u3002 <\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<\/p><\/div>\n<p>\u516c\u53f8\u901a\u8fc7\u56fd\u5bb6\u836f\u76d1\u5c40\u7f51\u7ad9\u83b7\u6089\uff0c\u7d22\u51e1\u66ff\u5c3c\u7528\u4e8e\u6cbb\u7597\u80f0\u817a\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u7684\u836f\u54c1\u6ce8\u518c\u5ba1\u6279\u5df2\u5b8c\u6210\uff0c\u6279\u4ef6\u6b63\u5728\u5236\u4f5c\u4e2d\u3002<\/p>\n<p>\u548c\u9ec4\u533b\u836f\u9996\u5e2d\u6267\u884c\u5b98\u8d3a\u96bd\u5148\u751f\uff08Mr. Christian Hogg\uff09\u8868\u793a\uff1a\u201c\u81ea\u4eca\u5e741\u6708\u4e0a\u5e02\u4ee5\u6765\uff0c\u7d22\u51e1\u66ff\u5c3c\u51ed\u501f\u5176\u72ec\u7279\u7684\u6291\u5236\u8840\u7ba1\u751f\u6210\u548c\u4fc3\u8fdb\u5bf9\u80bf\u7624\u7ec6\u80de\u514d\u75ab\u53cd\u5e94\u7684\u53cc\u91cd\u4f5c\u7528\u673a\u5236\uff0c\u60e0\u53ca\u975e\u80f0\u817a\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u60a3\u8005\u3002\u968f\u7740\u65b0\u9002\u5e94\u75c7\u83b7\u6279\uff0c\u73b0\u5728\u6211\u4eec\u4e5f\u80fd\u591f\u4e3a\u80f0\u817a\u6765\u6e90\u7684\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u60a3\u8005\u63d0\u4f9b\u8fd9\u79cd\u72ec\u7279\u7684\u521b\u65b0\u7597\u6cd5\u3002\u201d<\/p>\n<p>\u7d22\u51e1\u66ff\u5c3c\u5728\u4e2d\u56fd\u5e02\u573a\u4ee5\u5546\u54c1\u540d\u82cf\u6cf0\u8fbe&reg;\uff08\u82f1\u6587\u5546\u6807\uff1aSulanda&reg;\uff09\u8fdb\u884c\u9500\u552e\u3002&nbsp;<\/p>\n<p>\u548c\u9ec4\u533b\u836f\u7684\u80bf\u7624\u4e13\u79d1\u5546\u4e1a\u5316\u56e2\u961f\u76ee\u524d\u8986\u76d6\u5168\u4e2d\u56fd2,500\u591a\u5bb6\u533b\u9662\u3002\u8be5\u56e2\u961f\u7531\u5728\u4e2d\u56fd\u80bf\u7624\u4ea7\u54c1\u5546\u4e1a\u5316\u53ca\u5728\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u9886\u57df\u5177\u6709\u4e30\u5bcc\u7ecf\u9a8c\u7684\u9886\u5bfc\u56e2\u961f\u5e26\u9886\u3002<\/p>\n<p>\u6b64\u6b21\u56fd\u5bb6\u836f\u76d1\u5c40\u7684\u6279\u51c6\u662f\u57fa\u4e8e\u4e00\u9879\u7d22\u51e1\u66ff\u5c3c\u6cbb\u7597\u665a\u671f\u80f0\u817a\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u60a3\u8005\u7684\u4e2d\u56fdIII\u671f\u4e34\u5e8a\u8bd5\u9a8cSANET-p\u7684\u7814\u7a76\u7ed3\u679c\uff08clinicaltrials.gov\u6ce8\u518c\u53f7<a target=\"_blank\" href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02589821\" rel=\"nofollow noopener\">NCT02589821<\/a>\uff09\u3002\u8be5\u7814\u7a76\u5728\u9884\u8bbe\u7684\u4e2d\u671f\u5206\u6790\u4e2d\u6210\u529f\u8fbe\u5230\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\uff08\u201cPFS\u201d\uff09\u8fd9\u4e00\u9884\u8bbe\u7684\u4e3b\u8981\u7ec8\u70b9\u5e76\u63d0\u524d\u7ec8\u6b62\u7814\u7a76\u3002\u8be5\u7814\u7a76\u7684\u79ef\u6781\u7ed3\u679c\u4e8e2020\u5e749\u6708\u5728\u6b27\u6d32\u80bf\u7624\u5185\u79d1\u5b66\u4f1a\uff08ESMO\uff09\u5e74\u4f1a\u4e0a\u4ee5\u53e3\u5934\u62a5\u544a\u7684\u5f62\u5f0f\u516c\u5e03\uff0c\u5e76\u540c\u6b65\u4e8e\u300a\u67f3\u53f6\u5200&middot;\u80bf\u7624\u5b66\u300b\u4e0a\u53d1\u8868\u3002[1] \u7d22\u51e1\u66ff\u5c3c\u6cbb\u7597\u7ec4\u60a3\u8005\u7684\u4e2d\u4f4dPFS \u4e3a10.9\u4e2a\u6708\uff0c\u5b89\u6170\u5242\u7ec4\u60a3\u8005\u5219\u4e3a3.7\u4e2a\u6708\uff08HR 0.491\uff1b95% CI 0.391 \u2013 0.755\uff1bp =0.0011\uff09\u3002\u5728\u5927\u591a\u6570\u4e3b\u8981\u4e9a\u7ec4\u7684\u80f0\u817a\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u60a3\u8005\u4e2d\u5747\u89c2\u5bdf\u5230\u83b7\u76ca\u3002\u7d22\u51e1\u66ff\u5c3c\u5177\u6709\u53ef\u63a7\u7684\u5b89\u5168\u6027\uff0c\u5e76\u4e0e\u8fc7\u5f80\u7814\u7a76\u4e2d\u7684\u89c2\u5bdf\u7ed3\u679c\u4e00\u81f4\u3002\u5927\u591a\u6570\u60a3\u8005\u5bf9\u6cbb\u7597\u7684\u8010\u53d7\u6027\u826f\u597d\uff0c\u7d22\u51e1\u66ff\u5c3c\u7ec4\u56e0\u6cbb\u7597\u671f\u95f4\u4e0d\u826f\u4e8b\u4ef6\u800c\u5bfc\u81f4\u6cbb\u7597\u4e2d\u65ad\u7684\u6bd4\u4f8b\u4e3a 10.6%\uff0c\u800c\u5b89\u6170\u5242\u7ec4\u4e3a 6.8%\u3002<\/p>\n<p>\u4e2d\u56fd\u4e8e2020\u5e74\u4f30\u8ba1\u7ea6\u670971,300\u4f8b\u65b0\u8bca\u65ad\u7684\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u75c5\u4f8b\u3002\u6309\u7167\u4e2d\u56fd\u7684\u53d1\u75c5\u7387\u4e0e\u6d41\u884c\u7387\u6bd4\u4f8b\u4f30\u7b97\uff0c\u4e2d\u56fd\u603b\u5171\u6216\u6709\u9ad8\u8fbe\u4e09\u5341\u4e07\u540d\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u60a3\u8005\u3002[2]&nbsp;<\/p>\n<p><b>\u5173\u4e8e\u795e\u7ecf\u5185\u5206\u6ccc\u7624<\/b><\/p>\n<p>\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u8d77\u6e90\u4e8e\u4e0e\u795e\u7ecf\u7cfb\u7edf\u76f8\u4e92\u4f5c\u7528\u7684\u7ec6\u80de\u6216\u4ea7\u751f\u6fc0\u7d20\u7684\u817a\u4f53\u3002\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u53ef\u8d77\u6e90\u4e8e\u4f53\u5185\u5f88\u591a\u90e8\u4f4d\uff0c\u6700\u5e38\u89c1\u4e8e\u6d88\u5316\u9053\u6216\u80ba\u90e8\uff0c\u53ef\u4e3a\u826f\u6027\u6216\u6076\u6027\u80bf\u7624\u3002\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u901a\u5e38\u5206\u4e3a\u80f0\u817a\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u548c\u975e\u80f0\u817a\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u4e24\u5927\u7c7b\u3002\u83b7\u6279\u7684\u9776\u5411\u6cbb\u7597\u5305\u62ec\u7d22\u5766&reg;\uff08\u82f9\u679c\u9178\u8212\u5c3c\u66ff\u5c3c\uff0c\u4ec5\u7528\u4e8e\u6cbb\u7597\u80f0\u817a\u795e\u7ecf\u5185\u5206\u6ccc\u7624\uff09\u548c\u7528\u4e8e\u6cbb\u7597\u80f0\u817a\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u53ca\u9ad8\u5ea6\u5206\u5316\u7684\u975e\u529f\u80fd\u6027\u80c3\u80a0\u9053\u6216\u80ba\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u7684\u98de\u5c3c\u59a5&reg;\uff08\u4f9d\u7ef4\u83ab\u53f8\uff09\u3002<\/p>\n<p>\u636eFrost &amp; Sullivan\u516c\u53f8\u4f30\u8ba1\uff0c2020\u5e74\u7f8e\u56fd\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u65b0\u8bca\u65ad\u75c5\u4f8b\u4e3a19,700\u4f8b\u3002\u503c\u5f97\u5173\u6ce8\u7684\u662f\uff0c\u4e0e\u5176\u4ed6\u80bf\u7624\u76f8\u6bd4\uff0c\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u60a3\u8005\u7684\u751f\u5b58\u671f\u76f8\u5bf9\u8f83\u957f\u3002\u56e0\u6b64\uff0c\u636e\u4f30\u8ba1\u7f8e\u56fd\u4e8e2018\u5e74\u7ea6\u6709141,000\u540d\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u60a3\u8005\u3002<\/p>\n<p><b>\u5173\u4e8e\u7d22\u51e1\u66ff\u5c3c\uff08\u4e2d\u56fd\u5546\u54c1\u540d\uff1a\u82cf\u6cf0\u8fbe&reg;\uff09<\/b><\/p>\n<p>\u7d22\u51e1\u66ff\u5c3c\uff08surufatinib\uff09\u662f\u4e00\u79cd\u65b0\u578b\u7684\u53e3\u670d\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5242\uff0c\u5177\u6709\u6297\u8840\u7ba1\u751f\u6210\u548c\u514d\u75ab\u8c03\u8282\u53cc\u91cd\u6d3b\u6027\u3002\u7d22\u51e1\u66ff\u5c3c\u53ef\u901a\u8fc7\u6291\u5236\u8840\u7ba1\u5185\u76ae\u751f\u957f\u56e0\u5b50\u53d7\u4f53\uff08VEGFR\uff09\u548c\u6210\u7ea4\u7ef4\u7ec6\u80de\u751f\u957f\u56e0\u5b50\u53d7\u4f53\uff08FGFR\uff09\u4ee5\u963b\u65ad\u80bf\u7624\u8840\u7ba1\u751f\u6210\uff0c\u5e76\u53ef\u6291\u5236\u96c6\u843d\u523a\u6fc0\u56e0\u5b501\u53d7\u4f53\uff08CSF-1R\uff09\uff0c\u901a\u8fc7\u8c03\u8282\u80bf\u7624\u76f8\u5173\u5de8\u566c\u7ec6\u80de\uff0c\u4fc3\u8fdb\u673a\u4f53\u5bf9\u80bf\u7624\u7ec6\u80de\u7684\u514d\u75ab\u5e94\u7b54\u3002\u7d22\u51e1\u66ff\u5c3c\u72ec\u7279\u7684\u53cc\u91cd\u673a\u5236\u80fd\u4ea7\u751f\u534f\u540c\u6297\u80bf\u7624\u6d3b\u6027\uff0c\u4f7f\u5176\u4e3a\u4e0e\u5176\u4ed6\u514d\u75ab\u7597\u6cd5\u7684\u8054\u5408\u4f7f\u7528\u7684\u7406\u60f3\u9009\u62e9\u3002<\/p>\n<p>\u548c\u9ec4\u533b\u836f\u76ee\u524d\u62e5\u6709\u7d22\u51e1\u66ff\u5c3c\u5728\u5168\u7403\u8303\u56f4\u5185\u7684\u6240\u6709\u6743\u5229\u3002<\/p>\n<p><b>\u7d22\u51e1\u66ff\u5c3c\u5f00\u53d1\u8ba1\u5212<\/b><\/p>\n<p>\u7f8e\u56fd\u4e0e\u6b27\u6d32\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u7814\u7a76\uff1a\u5728\u7f8e\u56fd\uff0c\u7d22\u51e1\u66ff\u5c3c\u4e8e2020\u5e744\u6708\u88ab\u6388\u4e88<a target=\"_blank\" href=\"https:\/\/www.hutch-med.com\/sc\/surufatinib-granted-us-fda-fast-track-designations\/\" rel=\"nofollow noopener\">\u5feb\u901f\u901a\u9053\u8d44\u683c<\/a>\uff0c\u7528\u4e8e\u6cbb\u7597\u80f0\u817a\u548c\u975e\u80f0\u817a\u795e\u7ecf\u5185\u5206\u6ccc\u7624\uff0c\u5e76\u4e8e2019\u5e7411\u6708\u88ab\u6388\u4e88\u201c<a target=\"_blank\" href=\"https:\/\/www.hutch-med.com\/sc\/surufatinib-fda-orphan-drug-designation\/\" rel=\"nofollow noopener\">\u5b64\u513f\u836f<\/a>\u201d\u8d44\u683c\uff0c\u7528\u4e8e\u6cbb\u7597\u80f0\u817a\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u3002\u7d22\u51e1\u66ff\u5c3c\u7684\u7f8e\u56fd\u65b0\u836f\u4e0a\u5e02\u7533\u8bf7\u5df2\u4e8e2021\u5e744\u6708<a target=\"_blank\" href=\"https:\/\/www.hutch-med.com\/sc\/hutchmed-completes-rolling-submission-of-nda-to-u-s-fda-for-surufatinib-for-the-treatment-of-advanced-nets\/\" rel=\"nofollow noopener\">\u5411FDA\u63d0\u4ea4<\/a>\uff0c\u5e76\u8ba1\u5212\u5176\u540e\u5411\u6b27\u6d32\u836f\u54c1\u7ba1\u7406\u5c40\uff08EMA\uff09\u63d0\u4ea4\u6b27\u6d32\u4e0a\u5e02\u8bb8\u53ef\u7533\u8bf7\u3002\u4ee5\u4e0a\u7533\u8bf7\u5747\u662f\u57fa\u4e8e\u5df2\u5b8c\u6210\u7684SANET-ep\u548cSANET-p\u7814\u7a76\uff0c\u4ee5\u53ca\u7d22\u51e1\u66ff\u5c3c\u5728\u7f8e\u56fd\u6cbb\u7597\u975e\u80f0\u817a\u548c\u80f0\u817a\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u60a3\u8005\u7684\u73b0\u6709\u6570\u636e\uff08clinicaltrials.gov \u6ce8\u518c\u53f7<u><a target=\"_blank\" href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02549937\" rel=\"nofollow noopener\">NCT02549937<\/a><\/u>\uff09\u3002<\/p>\n<p><i>\u4e2d\u56fd\u975e\u80f0\u817a\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u7814\u7a76\uff1a<\/i>\u7d22\u51e1\u66ff\u5c3c\u4e8e2020\u5e7412\u670830\u65e5\u83b7\u56fd\u5bb6\u836f\u76d1\u5c40<a target=\"_blank\" href=\"https:\/\/www.hutch-med.com\/sc\/chi-med-announces-the-nmpa-approval-of-surufatinib-sulanda-in-china-for-epnet\/\" rel=\"nofollow noopener\">\u6279\u51c6<\/a>\u7528\u4e8e\u6cbb\u7597\u975e\u80f0\u817a\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u3002\u7d22\u51e1\u66ff\u5c3c\u5728\u4e2d\u56fd\u5e02\u573a\u4ee5\u5546\u54c1\u540d\u82cf\u6cf0\u8fbe&reg;\u9500\u552e\u3002\u6b64\u83b7\u6279\u662f\u57fa\u4e8e\u4e00\u9879\u7d22\u51e1\u66ff\u5c3c\u6cbb\u7597\u665a\u671f\u975e\u80f0\u817a\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u60a3\u8005\u7684\u4e2d\u56fdIII\u671f\u4e34\u5e8a\u8bd5\u9a8cSANET-ep\u7684\u7814\u7a76\u7ed3\u679c\uff08clinicaltrials.gov\u6ce8\u518c\u53f7<a target=\"_blank\" href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02588170\" rel=\"nofollow noopener\">NCT02588170<\/a>\uff09\u3002\u8be5\u7814\u7a76\u5728\u4e2d\u671f\u5206\u6790\u4e2d\u6210\u529f\u8fbe\u5230PFS\u8fd9\u4e00\u9884\u8bbe\u7684\u4e3b\u8981\u7ec8\u70b9\u3002\u8be5\u7814\u7a76\u7684<u><a target=\"_blank\" href=\"https:\/\/www.chi-med.com\/sc\/chi-med-to-discuss-surufatinib-phase-iii-and-u-s-phase-i-ib-efficacy-and-safety-data-presented-at-the-2019-esmo-annual-meeting\/\" rel=\"nofollow noopener\">\u79ef\u6781\u7ed3\u679c<\/a><\/u>\u4e8e2019\u5e74\u6b27\u6d32\u80bf\u7624\u5185\u79d1\u5b66\u4f1a(ESMO)\u5e74\u4f1a\u4e0a\u4ee5\u53e3\u5934\u62a5\u544a\u7684\u5f62\u5f0f\u516c\u5e03\uff0c\u5e76\u4e8e2020\u5e749\u6708\u5728\u300a\u67f3\u53f6\u5200&middot;\u80bf\u7624\u5b66\u300b\u4e0a<a target=\"_blank\" href=\"https:\/\/doi.org\/10.1016\/S1470-2045(20)30496-4\" rel=\"nofollow noopener\">\u53d1\u8868<\/a>\u3002[3] \u7d22\u51e1\u66ff\u5c3c\u6cbb\u7597\u7ec4\u60a3\u8005\u7684\u4e2d\u4f4dPFS\u663e\u8457\u5ef6\u957f\u4e3a9.2\u4e2a\u6708\uff0c\u5b89\u6170\u5242\u7ec4\u60a3\u8005\u5219\u4e3a3.8\u4e2a\u6708\uff08HR 0.334\uff1b95% CI 0.223 \u2013 0.499\uff1bp &lt;0.0001\uff09\u3002\u7d22\u51e1\u66ff\u5c3c\u5177\u6709\u53ef\u63a5\u53d7\u7684\u5b89\u5168\u6027\u7279\u5f81\uff0c\u6700\u5e38\u89c1\u76843\u7ea7\u6216\u4ee5\u4e0a\u6cbb\u7597\u76f8\u5173\u4e0d\u826f\u4e8b\u4ef6\u662f\u9ad8\u8840\u538b\uff08\u7d22\u51e1\u66ff\u5c3c\u7ec4\u60a3\u8005:36%; \u5b89\u6170\u5242\u7ec4\u60a3\u8005:13%\uff09\u3001\u86cb\u767d\u5c3f\uff08\u7d22\u51e1\u66ff\u5c3c\u7ec4\u60a3\u8005:19%; \u5b89\u6170\u5242\u7ec4\u60a3\u8005: 0%\uff09\u548c\u8d2b\u8840\uff08\u7d22\u51e1\u66ff\u5c3c\u7ec4\u60a3\u8005:5%; \u5b89\u6170\u5242\u7ec4\u60a3\u8005:3%\uff09\u3002<\/p>\n<p><i>\u4e2d\u56fd\u80c6\u9053\u764c\u7814\u7a76\uff1a<\/i>\u548c\u9ec4\u533b\u836f\u4e8e2019\u5e743\u6708\u542f\u52a8\u4e86\u4e00\u9879IIb\/III\u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u65e8\u5728\u5bf9\u6bd4\u7d22\u51e1\u66ff\u5c3c\u548c\u5361\u57f9\u4ed6\u6ee8\u6cbb\u7597\u4e00\u7ebf\u5316\u7597\u540e\u8fdb\u5c55\u7684\u665a\u671f\u80c6\u9053\u764c\u60a3\u8005\u3002\u8be5\u7814\u7a76\u7684\u4e3b\u8981\u7ec8\u70b9\u4e3a\u603b\u751f\u5b58\u671f\uff08OS\uff09\uff08clinicaltrials.gov \u6ce8\u518c\u53f7\uff1a<u><a target=\"_blank\" href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03873532\" rel=\"nofollow noopener\">NCT03873532<\/a><\/u>\uff09\u3002<\/p>\n<p><i>\u514d\u75ab\u8054\u5408\u7597\u6cd5\uff1a<\/i>\u548c\u9ec4\u533b\u836f\u8fbe\u6210\u4e86\u6570\u4e2a\u5408\u4f5c\u534f\u8bae\uff0c\u4ee5\u8bc4\u4f30\u7d22\u51e1\u66ff\u5c3c\u4e0ePD-1\u5355\u514b\u9686\u6297\u4f53\u8054\u5408\u7597\u6cd5\u7684\u5b89\u5168\u6027\u3001\u8010\u53d7\u6027\u548c\u7597\u6548\uff0c\u5305\u62ec\u5df2\u4e8e\u4e2d\u56fd\u83b7\u6279\u5355\u836f\u7597\u6cd5\u7684<a target=\"_blank\" href=\"https:\/\/www.chi-med.com\/sc\/chi-med-and-beigene-collaboration-to-evaluate-surufatinib-and-fruquintinib-with-tislelizumab-combinations\/\" rel=\"nofollow noopener\">\u767e\u6cfd\u5b89&reg;<\/a>\uff08\u66ff\u96f7\u5229\u73e0\u5355\u6297\uff09\u3001<u><a target=\"_blank\" href=\"https:\/\/www.chi-med.com\/sc\/chi-med-initiates-a-phase-ii-trial-of-surufatinib-in-combination-with-tuoyi-in-patients-with-advanced-solid-tumors\/\" rel=\"nofollow noopener\">\u62d3\u76ca&reg;<\/a><\/u>\uff08\u7279\u745e\u666e\u5229\u5355\u6297\uff09\u548c<u><a target=\"_blank\" href=\"https:\/\/www.chi-med.com\/sc\/innovent-and-chi-med-expand-global-collaboration-to-evaluate-the-combination-of-sintilimab-and-surufatinib-in-solid-tumors\/\" rel=\"nofollow noopener\">\u8fbe\u4f2f\u8212&reg;<\/a><\/u>\uff08\u4fe1\u8fea\u5229\u5355\u6297\uff09\u3002<\/p>\n<p><b><i>\u5173\u4e8e\u548c\u9ec4\u533b\u836f<\/i><\/b><\/p>\n<p>\u548c\u9ec4\u533b\u836f\uff08\u7eb3\u65af\u8fbe\u514b\/\u4f26\u6566\u8bc1\u4ea4\u6240\uff1aHCM\uff09\uff08\u524d\u79f0\uff1a\u548c\u9ec4\u4e2d\u56fd\u533b\u836f\u79d1\u6280\uff09\u662f\u4e00\u5bb6\u5904\u4e8e\u5546\u4e1a\u5316\u9636\u6bb5\u7684\u521b\u65b0\u578b\u751f\u7269\u533b\u836f\u516c\u53f8\uff0c\u81f4\u529b\u4e8e\u53d1\u73b0\u3001\u5168\u7403\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u6cbb\u7597\u764c\u75c7\u548c\u514d\u75ab\u6027\u75be\u75c5\u7684\u9776\u5411\u836f\u7269\u548c\u514d\u75ab\u7597\u6cd5\u3002\u8d85\u8fc71,300\u4eba\u7684\u4e13\u4e1a\u56e2\u961f\u5df2\u5c06\u81ea\u4e3b\u53d1\u73b0\u768410\u4e2a\u5019\u9009\u764c\u75c7\u836f\u7269\u63a8\u8fdb\u5230\u5728\u5168\u7403\u5f00\u5c55\u4e34\u5e8a\u7814\u7a76\uff0c\u5176\u4e2d\u9996\u4e24\u4e2a\u521b\u65b0\u80bf\u7624\u836f\u7269\u73b0\u5df2\u83b7\u6279\u5e76\u4e0a\u5e02\u3002\u6b32\u4e86\u89e3\u66f4\u591a\u8be6\u60c5\uff0c\u8bf7\u8bbf\u95ee\uff1a<u><a target=\"_blank\" href=\"https:\/\/www.hutch-med.com\/sc\/home\/\" rel=\"nofollow noopener\">www.hutch-med.com<\/a><\/u>\u6216\u5173\u6ce8\u6211\u4eec\u7684<a target=\"_blank\" href=\"https:\/\/www.linkedin.com\/company\/hutchmed\" rel=\"nofollow noopener\">\u9886\u82f1\u4e13\u9875<\/a>\u3002<\/p>\n<p><b><i>\u524d\u77bb\u6027\u9648\u8ff0<\/i><\/b><\/p>\n<p><i>\u672c\u516c\u544a\u5305\u542b<\/i><i>1995\u5e74\u300a\u7f8e\u56fd\u79c1\u4eba\u8bc1\u5238\u8bc9\u8bbc\u6539\u9769\u6cd5\u6848\u300b\u201c\u5b89\u5168\u6e2f\u201d\u6761\u6b3e\u4e2d\u5b9a\u4e49\u7684\u524d\u77bb\u6027\u9648\u8ff0\u3002\u8fd9\u4e9b\u524d\u77bb\u6027\u9648\u8ff0\u53cd\u6620\u4e86\u548c\u9ec4\u533b\u836f\u76ee\u524d\u5bf9\u672a\u6765\u4e8b\u4ef6\u7684\u9884\u671f\uff0c\u5305\u62ec\u5bf9\u7d22\u51e1\u66ff\u5c3c\u4e8e\u4e2d\u56fd\u5546\u4e1a\u5316\u4e0a\u5e02\u7684\u9884\u671f\uff0c\u5176\u81ea\u6709\u80bf\u7624\u5546\u4e1a\u5316\u56e2\u961f\u5feb\u901f\u548c\u5e7f\u6cdb\u63a8\u5e7f\u7d22\u51e1\u66ff\u5c3c\u7684\u80fd\u529b\uff0c\u7d22\u51e1\u66ff\u5c3c\u5728\u4e2d\u56fd\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u60a3\u8005\u4e2d\u7684\u6f5c\u5728\u5e02\u573a\uff0c\u4ee5\u53ca\u7d22\u51e1\u66ff\u5c3c\u5728\u4e2d\u56fd\u3001\u7f8e\u56fd\u548c\u5176\u4ed6\u5730\u533a\u9488\u5bf9\u6b64\u9002\u5e94\u75c7\u548c\u5176\u4ed6\u9002\u5e94\u75c7\u7684\u8fdb\u4e00\u6b65\u4e34\u5e8a\u7814\u7a76\u8ba1\u5212\u3002\u524d\u77bb\u6027\u9648\u8ff0\u6d89\u53ca\u98ce\u9669\u548c\u4e0d\u786e\u5b9a\u6027\u3002\u6b64\u7c7b\u98ce\u9669\u548c\u4e0d\u786e\u5b9a\u6027\u5305\u62ec\u4e0b\u5217\u5047\u8bbe\uff1a\u548c\u9ec4\u533b\u836f\u5546\u4e1a\u5316\u7d22\u51e1\u66ff\u5c3c\u7684\u80fd\u529b\uff0c\u6240\u6709\u63a5\u53d7\u7d22\u51e1\u66ff\u5c3c\u5904\u65b9\u7684\u60a3\u8005\u53ef\u83b7\u5f97\u4e0e\u4e34\u5e8a\u8bd5\u9a8c\u4e2d\u4f7f\u7528\u7d22\u51e1\u66ff\u5c3c\u8fbe\u5230\u76f8\u540c\u7684\u6536\u76ca\uff0c\u4e0d\u4f1a\u51fa\u73b0\u4efb\u4f55\u53ef\u80fd\u5bfc\u81f4\u56fd\u5bb6\u836f\u76d1\u5c40\u5c06\u7d22\u51e1\u66ff\u5c3c\u4ece\u5e02\u573a\u4e0a\u64a4\u51fa\u7684\u672a\u77e5\u526f\u4f5c\u7528\uff0c\u548c\u9ec4\u533b\u836f\u4e3a\u7d22\u51e1\u66ff\u5c3c\u8fdb\u4e00\u6b65\u4e34\u5e8a\u5f00\u53d1\u8ba1\u5212\u63d0\u4f9b\u8d44\u91d1\u5e76\u5b9e\u73b0\u53ca\u5b8c\u6210\u7684\u80fd\u529b\uff0c\u6b64\u7c7b\u4e8b\u4ef6\u53d1\u751f\u7684\u65f6\u95f4\uff0c\u4ee5\u53ca\u65b0\u51a0\u80ba\u708e\u5168\u7403\u5927\u6d41\u884c\u5bf9\u6574\u4f53\u7ecf\u6d4e\u3001\u76d1\u7ba1\u53ca\u653f\u6cbb\u72b6\u51b5\u5e26\u6765\u7684\u5f71\u54cd\u7b49\u3002\u6b64\u5916\uff0c\u7531\u4e8e\u90e8\u5206\u7814\u7a76\u8d56\u4e8e\u5c06\u5361\u57f9\u4ed6\u6ee8\u3001\u66ff\u96f7\u5229\u73e0\u5355\u6297\u3001\u62d3\u76ca&reg;\u3001\u8fbe\u4f2f\u8212&reg;\u4e0e\u7d22\u51e1\u66ff\u5c3c\u8054\u5408\u4f7f\u7528\uff0c\u56e0\u6b64\u6b64\u7c7b\u98ce\u9669\u548c\u4e0d\u786e\u5b9a\u6027\u5305\u62ec\u6709\u5173\u8fd9\u4e9b\u6cbb\u7597\u836f\u7269\u7684\u5b89\u5168\u6027\u3001\u7597\u6548\u3001\u4f9b\u5e94\u548c\u76d1\u7ba1\u6279\u51c6\u7684\u5047\u8bbe\u3002\u5f53\u524d\u548c\u6f5c\u5728\u6295\u8d44\u8005\u8bf7\u52ff\u8fc7\u5ea6\u4f9d\u8d56\u8fd9\u4e9b\u524d\u77bb\u6027\u9648\u8ff0\uff0c\u8fd9\u4e9b\u9648\u8ff0\u4ec5\u5728\u622a\u81f3\u672c\u516c\u544a\u53d1\u5e03\u5f53\u65e5\u6709\u6548\u3002\u6709\u5173\u8fd9\u4e9b\u98ce\u9669\u548c\u5176\u4ed6\u98ce\u9669\u7684\u8fdb\u4e00\u6b65\u8ba8\u8bba\uff0c\u8bf7\u67e5\u9605\u548c\u9ec4\u533b\u836f\u5411\u7f8e\u56fd\u8bc1\u5238\u4ea4\u6613\u59d4\u5458\u4f1a\u548cAIM\u63d0\u4ea4\u7684\u6587\u4ef6\u3002\u65e0\u8bba\u662f\u5426\u51fa\u73b0\u65b0\u4fe1\u606f\u3001\u672a\u6765\u4e8b\u4ef6\u6216\u60c5\u51b5\u6216\u5176\u4ed6\u56e0\u7d20\uff0c\u548c\u9ec4\u533b\u836f\u5747\u4e0d\u627f\u62c5\u66f4\u65b0\u6216\u4fee\u8ba2\u672c\u516c\u544a\u6240\u542b\u4fe1\u606f\u7684\u4e49\u52a1\u3002<\/i><\/p>\n<p><b><i>\u5185\u5e55\u6d88\u606f<\/i><\/b><\/p>\n<p><i>\u672c\u516c\u544a\u5305\u542b\uff08\u6b27\u76df\uff09\u7b2c<\/i><i>596\/2014\u53f7\u6761\u4f8b\u7b2c7\u6761\u89c4\u5b9a\u7684\u5185\u5e55\u6d88\u606f\u3002<\/i><\/p>\n<div>\n<table id=\"convertedTable0b47\" cellspacing=\"0\" cellpadding=\"0\" border=\"1\" class=\"prnbcc\">\n<tbody>\n<tr>\n<td class=\"prngen2\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">[1]&nbsp;Xu J, Shen L, Bai C, et al. Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study [published online ahead of print, 2020 Sep 20]. <i>Lancet Oncol.<\/i> 2020;&nbsp;S1470-2045(20)30493-9. <a target=\"_blank\" href=\"https:\/\/doi.org\/10.1016\/S1470-2045(20)30493-9\" class=\"prnews_a\" rel=\"nofollow noopener\">DOI: 10.1016\/S1470-2045(20)30493-9<\/a>.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">[2]&nbsp;\u636eFrost &amp; Sullivan\u516c\u53f8\u7684\u6570\u636e\uff0c\u5728\u4e2d\u56fd\u7531\u4e8e\u6cbb\u7597\u624b\u6bb5\u7f3a\u4e4f\uff0c\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u7684\u53d1\u75c5\u7387\u4e0e\u6d41\u884c\u7387\u6bd4\u4f8b\u4f30\u8ba1\u4e3a4.4\uff0c\u8f83\u7f8e\u56fd\u76847.4\u4e3a\u4f4e\u3002<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">[3]&nbsp;Xu J, Shen L, Zhou Z, et al. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study [published online ahead of print, 2020 Sep 20]. <i>Lancet Oncol.<\/i> 2020; S1470-2045(20)30496-4. <a target=\"_blank\" href=\"https:\/\/doi.org\/10.1016\/S1470-2045(20)30496-4\" class=\"prnews_a\" rel=\"nofollow noopener\">DOI: 10.1016\/S1470-2045(20)30496-4<\/a>.<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n<p>&nbsp;<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\">  <\/div>\n<p>\u76f8\u5173\u94fe\u63a5 :<\/p>\n<blockquote class=\"wp-embedded-content\" data-secret=\"UP0sDFNBYc\"><p><a href=\"https:\/\/www.hutch-med.com\/\">Home<\/a><\/p><\/blockquote>\n<p><iframe class=\"wp-embedded-content\" sandbox=\"allow-scripts\" security=\"restricted\" style=\"position: absolute; clip: rect(1px, 1px, 1px, 1px);\" title=\"&#8220;Home&#8221; &#8212; HUTCHMED\" src=\"https:\/\/www.hutch-med.com\/embed\/#?secret=UP0sDFNBYc\" data-secret=\"UP0sDFNBYc\" width=\"600\" height=\"338\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\"><\/iframe><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&#8211;&nbsp;\u82cf\u6cf0\u8fbe&reg;\u5728\u4e2d\u56fd\u83b7\u6279\u7684\u7b2c\u4e8c\u9879\u65b0\u836f\u4e0a\u5e02\u7533\u8bf7 &#8211; &#8211;&nbsp;SANET-p\u5173\u952e\u6027III\u671f\u7814\u7a76\u663e\u793a\uff0c\u7d22\u51e1\u66ff\u5c3c\u964d\u4f4e\u665a\u671f\u80f0\u817a\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u60a3\u8005\u7684\u75be\u75c5\u8fdb\u5c55\u6216\u6b7b\u4ea1\u98ce\u9669\u8fbe51% &#8211; \u9999\u6e2f2021\u5e746\u670821\u65e5 \/\u7f8e\u901a\u793e\/ &#8212; \u548c\u9ec4\u533b\u836f\uff08\u4e2d\u56fd\uff09\u6709\u9650\u516c\u53f8\uff08\u7b80\u79f0\u201c\u548c\u9ec4\u533b\u836f\u201d\u6216\u201cHUTCHMED\u201d\uff09\uff08\u7eb3\u65af\u8fbe\u514b\/\u4f26\u6566\u8bc1\u4ea4\u6240\uff1aHCM\uff09\u4eca\u65e5\u5ba3\u5e03\u7d22\u51e1\u66ff\u5c3c\u6b63\u5f0f\u83b7\u4e2d\u56fd\u56fd\u5bb6\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\uff08\u201c\u56fd\u5bb6\u836f\u76d1\u5c40\u201d\uff09\u6279\u51c6\u7528\u4e8e\u6cbb\u7597\u665a\u671f\u80f0\u817a\u795e\u7ecf\u5185\u5206\u6ccc\u7624\uff08pNETs\uff09\u3002\u8fd9\u662f\u7ee7\u7d22\u51e1\u66ff\u5c3c\u4e8e 2020\u5e7412\u6708\u5728\u4e2d\u56fd\u83b7\u6279\u7528\u4e8e\u6cbb\u7597\u665a\u671f\u975e\u80f0\u817a\u795e\u7ecf\u5185\u5206\u6ccc\u7624\uff08epNETs\uff09\u4e4b\u540e\uff0c\u7d22\u51e1\u66ff\u5c3c\u7b2c\u4e8c\u9879\u83b7\u6279\u7684\u65b0\u836f\u4e0a\u5e02\u7533\u8bf7\u3002 \u516c\u53f8\u901a\u8fc7\u56fd\u5bb6\u836f\u76d1\u5c40\u7f51\u7ad9\u83b7\u6089\uff0c\u7d22\u51e1\u66ff\u5c3c\u7528\u4e8e\u6cbb\u7597\u80f0\u817a\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u7684\u836f\u54c1\u6ce8\u518c\u5ba1\u6279\u5df2\u5b8c\u6210\uff0c\u6279\u4ef6\u6b63\u5728\u5236\u4f5c\u4e2d\u3002 \u548c\u9ec4\u533b\u836f\u9996\u5e2d\u6267\u884c\u5b98\u8d3a\u96bd\u5148\u751f\uff08Mr. Christian Hogg\uff09\u8868\u793a\uff1a\u201c\u81ea\u4eca\u5e741\u6708\u4e0a\u5e02\u4ee5\u6765\uff0c\u7d22\u51e1\u66ff\u5c3c\u51ed\u501f\u5176\u72ec\u7279\u7684\u6291\u5236\u8840\u7ba1\u751f\u6210\u548c\u4fc3\u8fdb\u5bf9\u80bf\u7624\u7ec6\u80de\u514d\u75ab\u53cd\u5e94\u7684\u53cc\u91cd\u4f5c\u7528\u673a\u5236\uff0c\u60e0\u53ca\u975e\u80f0\u817a\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u60a3\u8005\u3002\u968f\u7740\u65b0\u9002\u5e94\u75c7\u83b7\u6279\uff0c\u73b0\u5728\u6211\u4eec\u4e5f\u80fd\u591f\u4e3a\u80f0\u817a\u6765\u6e90\u7684\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u60a3\u8005\u63d0\u4f9b\u8fd9\u79cd\u72ec\u7279\u7684\u521b\u65b0\u7597\u6cd5\u3002\u201d \u7d22\u51e1\u66ff\u5c3c\u5728\u4e2d\u56fd\u5e02\u573a\u4ee5\u5546\u54c1\u540d\u82cf\u6cf0\u8fbe&reg;\uff08\u82f1\u6587\u5546\u6807\uff1aSulanda&reg;\uff09\u8fdb\u884c\u9500\u552e\u3002&nbsp; \u548c\u9ec4\u533b\u836f\u7684\u80bf\u7624\u4e13\u79d1\u5546\u4e1a\u5316\u56e2\u961f\u76ee\u524d\u8986\u76d6\u5168\u4e2d\u56fd2,500\u591a\u5bb6\u533b\u9662\u3002\u8be5\u56e2\u961f\u7531\u5728\u4e2d\u56fd\u80bf\u7624\u4ea7\u54c1\u5546\u4e1a\u5316\u53ca\u5728\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u9886\u57df\u5177\u6709\u4e30\u5bcc\u7ecf\u9a8c\u7684\u9886\u5bfc\u56e2\u961f\u5e26\u9886\u3002 \u6b64\u6b21\u56fd\u5bb6\u836f\u76d1\u5c40\u7684\u6279\u51c6\u662f\u57fa\u4e8e\u4e00\u9879\u7d22\u51e1\u66ff\u5c3c\u6cbb\u7597\u665a\u671f\u80f0\u817a\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u60a3\u8005\u7684\u4e2d\u56fdIII\u671f\u4e34\u5e8a\u8bd5\u9a8cSANET-p\u7684\u7814\u7a76\u7ed3\u679c\uff08clinicaltrials.gov\u6ce8\u518c\u53f7NCT02589821\uff09\u3002\u8be5\u7814\u7a76\u5728\u9884\u8bbe\u7684\u4e2d\u671f\u5206\u6790\u4e2d\u6210\u529f\u8fbe\u5230\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\uff08\u201cPFS\u201d\uff09\u8fd9\u4e00\u9884\u8bbe\u7684\u4e3b\u8981\u7ec8\u70b9\u5e76\u63d0\u524d\u7ec8\u6b62\u7814\u7a76\u3002\u8be5\u7814\u7a76\u7684\u79ef\u6781\u7ed3\u679c\u4e8e2020\u5e749\u6708\u5728\u6b27\u6d32\u80bf\u7624\u5185\u79d1\u5b66\u4f1a\uff08ESMO\uff09\u5e74\u4f1a\u4e0a\u4ee5\u53e3\u5934\u62a5\u544a\u7684\u5f62\u5f0f\u516c\u5e03\uff0c\u5e76\u540c\u6b65\u4e8e\u300a\u67f3\u53f6\u5200&middot;\u80bf\u7624\u5b66\u300b\u4e0a\u53d1\u8868\u3002[1] \u7d22\u51e1\u66ff\u5c3c\u6cbb\u7597\u7ec4\u60a3\u8005\u7684\u4e2d\u4f4dPFS \u4e3a10.9\u4e2a\u6708\uff0c\u5b89\u6170\u5242\u7ec4\u60a3\u8005\u5219\u4e3a3.7\u4e2a\u6708\uff08HR 0.491\uff1b95% CI 0.391 \u2013 0.755\uff1bp =0.0011\uff09\u3002\u5728\u5927\u591a\u6570\u4e3b\u8981\u4e9a\u7ec4\u7684\u80f0\u817a\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u60a3\u8005\u4e2d\u5747\u89c2\u5bdf\u5230\u83b7\u76ca\u3002\u7d22\u51e1\u66ff\u5c3c\u5177\u6709\u53ef\u63a7\u7684\u5b89\u5168\u6027\uff0c\u5e76\u4e0e\u8fc7\u5f80\u7814\u7a76\u4e2d\u7684\u89c2\u5bdf\u7ed3\u679c\u4e00\u81f4\u3002\u5927\u591a\u6570\u60a3\u8005\u5bf9\u6cbb\u7597\u7684\u8010\u53d7\u6027\u826f\u597d\uff0c\u7d22\u51e1\u66ff\u5c3c\u7ec4\u56e0\u6cbb\u7597\u671f\u95f4\u4e0d\u826f\u4e8b\u4ef6\u800c\u5bfc\u81f4\u6cbb\u7597\u4e2d\u65ad\u7684\u6bd4\u4f8b\u4e3a 10.6%\uff0c\u800c\u5b89\u6170\u5242\u7ec4\u4e3a 6.8%\u3002 \u4e2d\u56fd\u4e8e2020\u5e74\u4f30\u8ba1\u7ea6\u670971,300\u4f8b\u65b0\u8bca\u65ad\u7684\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u75c5\u4f8b\u3002\u6309\u7167\u4e2d\u56fd\u7684\u53d1\u75c5\u7387\u4e0e\u6d41\u884c\u7387\u6bd4\u4f8b\u4f30\u7b97\uff0c\u4e2d\u56fd\u603b\u5171\u6216\u6709\u9ad8\u8fbe\u4e09\u5341\u4e07\u540d\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u60a3\u8005\u3002[2]&nbsp; \u5173\u4e8e\u795e\u7ecf\u5185\u5206\u6ccc\u7624 \u795e\u7ecf\u5185\u5206\u6ccc\u7624\u8d77\u6e90\u4e8e\u4e0e\u795e\u7ecf\u7cfb\u7edf\u76f8\u4e92\u4f5c\u7528\u7684\u7ec6\u80de\u6216\u4ea7\u751f\u6fc0\u7d20\u7684\u817a\u4f53\u3002\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u53ef\u8d77\u6e90\u4e8e\u4f53\u5185\u5f88\u591a\u90e8\u4f4d\uff0c\u6700\u5e38\u89c1\u4e8e\u6d88\u5316\u9053\u6216\u80ba\u90e8\uff0c\u53ef\u4e3a\u826f\u6027\u6216\u6076\u6027\u80bf\u7624\u3002\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u901a\u5e38\u5206\u4e3a\u80f0\u817a\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u548c\u975e\u80f0\u817a\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u4e24\u5927\u7c7b\u3002\u83b7\u6279\u7684\u9776\u5411\u6cbb\u7597\u5305\u62ec\u7d22\u5766&reg;\uff08\u82f9\u679c\u9178\u8212\u5c3c\u66ff\u5c3c\uff0c\u4ec5\u7528\u4e8e\u6cbb\u7597\u80f0\u817a\u795e\u7ecf\u5185\u5206\u6ccc\u7624\uff09\u548c\u7528\u4e8e\u6cbb\u7597\u80f0\u817a\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u53ca\u9ad8\u5ea6\u5206\u5316\u7684\u975e\u529f\u80fd\u6027\u80c3\u80a0\u9053\u6216\u80ba\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u7684\u98de\u5c3c\u59a5&reg;\uff08\u4f9d\u7ef4\u83ab\u53f8\uff09\u3002 \u636eFrost &amp; Sullivan\u516c\u53f8\u4f30\u8ba1\uff0c2020\u5e74\u7f8e\u56fd\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u65b0\u8bca\u65ad\u75c5\u4f8b\u4e3a19,700\u4f8b\u3002\u503c\u5f97\u5173\u6ce8\u7684\u662f\uff0c\u4e0e\u5176\u4ed6\u80bf\u7624\u76f8\u6bd4\uff0c\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u60a3\u8005\u7684\u751f\u5b58\u671f\u76f8\u5bf9\u8f83\u957f\u3002\u56e0\u6b64\uff0c\u636e\u4f30\u8ba1\u7f8e\u56fd\u4e8e2018\u5e74\u7ea6\u6709141,000\u540d\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u60a3\u8005\u3002 \u5173\u4e8e\u7d22\u51e1\u66ff\u5c3c\uff08\u4e2d\u56fd\u5546\u54c1\u540d\uff1a\u82cf\u6cf0\u8fbe&reg;\uff09 \u7d22\u51e1\u66ff\u5c3c\uff08surufatinib\uff09\u662f\u4e00\u79cd\u65b0\u578b\u7684\u53e3\u670d\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5242\uff0c\u5177\u6709\u6297\u8840\u7ba1\u751f\u6210\u548c\u514d\u75ab\u8c03\u8282\u53cc\u91cd\u6d3b\u6027\u3002\u7d22\u51e1\u66ff\u5c3c\u53ef\u901a\u8fc7\u6291\u5236\u8840\u7ba1\u5185\u76ae\u751f\u957f\u56e0\u5b50\u53d7\u4f53\uff08VEGFR\uff09\u548c\u6210\u7ea4\u7ef4\u7ec6\u80de\u751f\u957f\u56e0\u5b50\u53d7\u4f53\uff08FGFR\uff09\u4ee5\u963b\u65ad\u80bf\u7624\u8840\u7ba1\u751f\u6210\uff0c\u5e76\u53ef\u6291\u5236\u96c6\u843d\u523a\u6fc0\u56e0\u5b501\u53d7\u4f53\uff08CSF-1R\uff09\uff0c\u901a\u8fc7\u8c03\u8282\u80bf\u7624\u76f8\u5173\u5de8\u566c\u7ec6\u80de\uff0c\u4fc3\u8fdb\u673a\u4f53\u5bf9\u80bf\u7624\u7ec6\u80de\u7684\u514d\u75ab\u5e94\u7b54\u3002\u7d22\u51e1\u66ff\u5c3c\u72ec\u7279\u7684\u53cc\u91cd\u673a\u5236\u80fd\u4ea7\u751f\u534f\u540c\u6297\u80bf\u7624\u6d3b\u6027\uff0c\u4f7f\u5176\u4e3a\u4e0e\u5176\u4ed6\u514d\u75ab\u7597\u6cd5\u7684\u8054\u5408\u4f7f\u7528\u7684\u7406\u60f3\u9009\u62e9\u3002 \u548c\u9ec4\u533b\u836f\u76ee\u524d\u62e5\u6709\u7d22\u51e1\u66ff\u5c3c\u5728\u5168\u7403\u8303\u56f4\u5185\u7684\u6240\u6709\u6743\u5229\u3002 \u7d22\u51e1\u66ff\u5c3c\u5f00\u53d1\u8ba1\u5212 \u7f8e\u56fd\u4e0e\u6b27\u6d32\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u7814\u7a76\uff1a\u5728\u7f8e\u56fd\uff0c\u7d22\u51e1\u66ff\u5c3c\u4e8e2020\u5e744\u6708\u88ab\u6388\u4e88\u5feb\u901f\u901a\u9053\u8d44\u683c\uff0c\u7528\u4e8e\u6cbb\u7597\u80f0\u817a\u548c\u975e\u80f0\u817a\u795e\u7ecf\u5185\u5206\u6ccc\u7624\uff0c\u5e76\u4e8e2019\u5e7411\u6708\u88ab\u6388\u4e88\u201c\u5b64\u513f\u836f\u201d\u8d44\u683c\uff0c\u7528\u4e8e\u6cbb\u7597\u80f0\u817a\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u3002\u7d22\u51e1\u66ff\u5c3c\u7684\u7f8e\u56fd\u65b0\u836f\u4e0a\u5e02\u7533\u8bf7\u5df2\u4e8e2021\u5e744\u6708\u5411FDA\u63d0\u4ea4\uff0c\u5e76\u8ba1\u5212\u5176\u540e\u5411\u6b27\u6d32\u836f\u54c1\u7ba1\u7406\u5c40\uff08EMA\uff09\u63d0\u4ea4\u6b27\u6d32\u4e0a\u5e02\u8bb8\u53ef\u7533\u8bf7\u3002\u4ee5\u4e0a\u7533\u8bf7\u5747\u662f\u57fa\u4e8e\u5df2\u5b8c\u6210\u7684SANET-ep\u548cSANET-p\u7814\u7a76\uff0c\u4ee5\u53ca\u7d22\u51e1\u66ff\u5c3c\u5728\u7f8e\u56fd\u6cbb\u7597\u975e\u80f0\u817a\u548c\u80f0\u817a\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u60a3\u8005\u7684\u73b0\u6709\u6570\u636e\uff08clinicaltrials.gov \u6ce8\u518c\u53f7NCT02549937\uff09\u3002 \u4e2d\u56fd\u975e\u80f0\u817a\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u7814\u7a76\uff1a\u7d22\u51e1\u66ff\u5c3c\u4e8e2020\u5e7412\u670830\u65e5\u83b7\u56fd\u5bb6\u836f\u76d1\u5c40\u6279\u51c6\u7528\u4e8e\u6cbb\u7597\u975e\u80f0\u817a\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u3002\u7d22\u51e1\u66ff\u5c3c\u5728\u4e2d\u56fd\u5e02\u573a\u4ee5\u5546\u54c1\u540d\u82cf\u6cf0\u8fbe&reg;\u9500\u552e\u3002\u6b64\u83b7\u6279\u662f\u57fa\u4e8e\u4e00\u9879\u7d22\u51e1\u66ff\u5c3c\u6cbb\u7597\u665a\u671f\u975e\u80f0\u817a\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u60a3\u8005\u7684\u4e2d\u56fdIII\u671f\u4e34\u5e8a\u8bd5\u9a8cSANET-ep\u7684\u7814\u7a76\u7ed3\u679c\uff08clinicaltrials.gov\u6ce8\u518c\u53f7NCT02588170\uff09\u3002\u8be5\u7814\u7a76\u5728\u4e2d\u671f\u5206\u6790\u4e2d\u6210\u529f\u8fbe\u5230PFS\u8fd9\u4e00\u9884\u8bbe\u7684\u4e3b\u8981\u7ec8\u70b9\u3002\u8be5\u7814\u7a76\u7684\u79ef\u6781\u7ed3\u679c\u4e8e2019\u5e74\u6b27\u6d32\u80bf\u7624\u5185\u79d1\u5b66\u4f1a(ESMO)\u5e74\u4f1a\u4e0a\u4ee5\u53e3\u5934\u62a5\u544a\u7684\u5f62\u5f0f\u516c\u5e03\uff0c\u5e76\u4e8e2020\u5e749\u6708\u5728\u300a\u67f3\u53f6\u5200&middot;\u80bf\u7624\u5b66\u300b\u4e0a\u53d1\u8868\u3002[3] \u7d22\u51e1\u66ff\u5c3c\u6cbb\u7597\u7ec4\u60a3\u8005\u7684\u4e2d\u4f4dPFS\u663e\u8457\u5ef6\u957f\u4e3a9.2\u4e2a\u6708\uff0c\u5b89\u6170\u5242\u7ec4\u60a3\u8005\u5219\u4e3a3.8\u4e2a\u6708\uff08HR 0.334\uff1b95% CI 0.223 \u2013 0.499\uff1bp &lt;0.0001\uff09\u3002\u7d22\u51e1\u66ff\u5c3c\u5177\u6709\u53ef\u63a5\u53d7\u7684\u5b89\u5168\u6027\u7279\u5f81\uff0c\u6700\u5e38\u89c1\u76843\u7ea7\u6216\u4ee5\u4e0a\u6cbb\u7597\u76f8\u5173\u4e0d\u826f\u4e8b\u4ef6\u662f\u9ad8\u8840\u538b\uff08\u7d22\u51e1\u66ff\u5c3c\u7ec4\u60a3\u8005:36%; \u5b89\u6170\u5242\u7ec4\u60a3\u8005:13%\uff09\u3001\u86cb\u767d\u5c3f\uff08\u7d22\u51e1\u66ff\u5c3c\u7ec4\u60a3\u8005:19%; \u5b89\u6170\u5242\u7ec4\u60a3\u8005: 0%\uff09\u548c\u8d2b\u8840\uff08\u7d22\u51e1\u66ff\u5c3c\u7ec4\u60a3\u8005:5%; \u5b89\u6170\u5242\u7ec4\u60a3\u8005:3%\uff09\u3002 \u4e2d\u56fd\u80c6\u9053\u764c\u7814\u7a76\uff1a\u548c\u9ec4\u533b\u836f\u4e8e2019\u5e743\u6708\u542f\u52a8\u4e86\u4e00\u9879IIb\/III\u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u65e8\u5728\u5bf9\u6bd4\u7d22\u51e1\u66ff\u5c3c\u548c\u5361\u57f9\u4ed6\u6ee8\u6cbb\u7597\u4e00\u7ebf\u5316\u7597\u540e\u8fdb\u5c55\u7684\u665a\u671f\u80c6\u9053\u764c\u60a3\u8005\u3002\u8be5\u7814\u7a76\u7684\u4e3b\u8981\u7ec8\u70b9\u4e3a\u603b\u751f\u5b58\u671f\uff08OS\uff09\uff08clinicaltrials.gov \u6ce8\u518c\u53f7\uff1aNCT03873532\uff09\u3002 \u514d\u75ab\u8054\u5408\u7597\u6cd5\uff1a\u548c\u9ec4\u533b\u836f\u8fbe\u6210\u4e86\u6570\u4e2a\u5408\u4f5c\u534f\u8bae\uff0c\u4ee5\u8bc4\u4f30\u7d22\u51e1\u66ff\u5c3c\u4e0ePD-1\u5355\u514b\u9686\u6297\u4f53\u8054\u5408\u7597\u6cd5\u7684\u5b89\u5168\u6027\u3001\u8010\u53d7\u6027\u548c\u7597\u6548\uff0c\u5305\u62ec\u5df2\u4e8e\u4e2d\u56fd\u83b7\u6279\u5355\u836f\u7597\u6cd5\u7684\u767e\u6cfd\u5b89&reg;\uff08\u66ff\u96f7\u5229\u73e0\u5355\u6297\uff09\u3001\u62d3\u76ca&reg;\uff08\u7279\u745e\u666e\u5229\u5355\u6297\uff09\u548c\u8fbe\u4f2f\u8212&reg;\uff08\u4fe1\u8fea\u5229\u5355\u6297\uff09\u3002 \u5173\u4e8e\u548c\u9ec4\u533b\u836f \u548c\u9ec4\u533b\u836f\uff08\u7eb3\u65af\u8fbe\u514b\/\u4f26\u6566\u8bc1\u4ea4\u6240\uff1aHCM\uff09\uff08\u524d\u79f0\uff1a\u548c\u9ec4\u4e2d\u56fd\u533b\u836f\u79d1\u6280\uff09\u662f\u4e00\u5bb6\u5904\u4e8e\u5546\u4e1a\u5316\u9636\u6bb5\u7684\u521b\u65b0\u578b\u751f\u7269\u533b\u836f\u516c\u53f8\uff0c\u81f4\u529b\u4e8e\u53d1\u73b0\u3001\u5168\u7403\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u6cbb\u7597\u764c\u75c7\u548c\u514d\u75ab\u6027\u75be\u75c5\u7684\u9776\u5411\u836f\u7269\u548c\u514d\u75ab\u7597\u6cd5\u3002\u8d85\u8fc71,300\u4eba\u7684\u4e13\u4e1a\u56e2\u961f\u5df2\u5c06\u81ea\u4e3b\u53d1\u73b0\u768410\u4e2a\u5019\u9009\u764c\u75c7\u836f\u7269\u63a8\u8fdb\u5230\u5728\u5168\u7403\u5f00\u5c55\u4e34\u5e8a\u7814\u7a76\uff0c\u5176\u4e2d\u9996\u4e24\u4e2a\u521b\u65b0\u80bf\u7624\u836f\u7269\u73b0\u5df2\u83b7\u6279\u5e76\u4e0a\u5e02\u3002\u6b32\u4e86\u89e3\u66f4\u591a\u8be6\u60c5\uff0c\u8bf7\u8bbf\u95ee\uff1awww.hutch-med.com\u6216\u5173\u6ce8\u6211\u4eec\u7684\u9886\u82f1\u4e13\u9875\u3002&hellip; <a class=\"read-more\" href=\"https:\/\/www.xinwengao.com\/cn\/pr\/2021062113010034755\">Read More<\/a><\/p>\n","protected":false},"author":556,"featured_media":34758,"comment_status":"close","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1965],"tags":[],"class_list":["post-34755","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-partnerships"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/34755","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/users\/556"}],"replies":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/comments?post=34755"}],"version-history":[{"count":1,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/34755\/revisions"}],"predecessor-version":[{"id":34757,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/34755\/revisions\/34757"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/media\/34758"}],"wp:attachment":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/media?parent=34755"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/categories?post=34755"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/tags?post=34755"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}